Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Pfizer (PFE) has entered into an agreement with Boltz to use the latter's biomolecular AI foundation models to tap into the ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...

Madrigal Pharmaceuticals (MDGL) stock is in focus as the company licenses Pfizer’s (PFE) experimental MASH therapy ervogastat. Read more here.